Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1.

doi:10.3748/wjg.v22.i12.3418

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1.

World journal of gastroenterology - 28 Mar 2016

Jacobson Ira, Zeuzem Stefan, Flisiak Robert, Knysz Brygida, Lueth Stefan, Zarebska-Michaluk Dorota, Janczewska Ewa, Ferenci Peter, Diago Moises, Zignego Anna Linda, Safadi Rifaat, Baruch Yaacov, Abdurakhmanov Dzhamal, Shafran Stephen, Thabut Dominique, Bruck Rafael, Gadano Adrian, Thompson Alexander James, Kopit Justin, McPhee Fiona, Michener Tracy, Hughes Eric A, Yin Philip D, Noviello Stephanie

Abstract excerpt

AIM: To evaluate daclatasvir vs telaprevir, each combined with peginterferon alfa-2a/ribavirin (pegIFN/RBV), in treatment-naive hepatitis C virus (HCV) genotype (GT) 1-infected patients. METHODS: In this phase 3, randomized, open-label, noninferiority study, 602 patients were randomly assigned (2:1) to daclatasvir vs telaprevir, stratified by IL28B rs12979860 host genotype (CC vs non-CC), cirrhosis status...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imidazoles

Share to Carbamates

Share to Interferons

Share to Interleukins

Share to Oligopeptides

Share to Polyethylene Glycols

Share to Pyrrolidines

Share to Valine

Source

Open in PubMed Open full text

Identifiers

PMID: 27022224
DOI: 10.3748/wjg.v22.i12.3418
PMCID: PMC4806200

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1.PMID 27022224Read ↗

Peginterferon Lambda-1a/Ribavirin with Daclatasvir or Peginterferon Alfa-2a/Ribavirin with Telaprevir for Chronic Hepatitis C Genotype 1b.Semantic proximity Read ↗

Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study.Semantic proximity Read ↗

A Randomized Study of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a in Combination with Ribavirin and Telaprevir in Patients with Genotype-1 Chronic Hepatitis C.Semantic proximity Read ↗

Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection.Semantic proximity Read ↗

Daclatasvir plus asunaprevir in treatment-naïve patients with hepatitis C virus genotype 1b infection.Semantic proximity Read ↗

Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection.Semantic proximity Read ↗

Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial.Semantic proximity Read ↗

A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection.Semantic proximity Read ↗

NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infectionSemantic proximity Read ↗

Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1 infection: A systematic review and meta-analysis.Semantic proximity Read ↗

Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.Semantic proximity Read ↗

All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.